Terms: = Breast cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC
464 results:
1. Surviving without BRCA2: mlh1 gets R-looped in to curtail genomic instability.
Johnson N
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557488
[TBL] [Abstract] [Full Text] [Related]
2. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study).
Hawranek C; Ehrencrona H; Öfverholm A; Hellquist BN; Rosén A
Trials; 2023 Dec; 24(1):810. PubMed ID: 38105176
[TBL] [Abstract] [Full Text] [Related]
3. ABERRANT METHYLATION OF cancer-RELATED GENES IN VIETNAMESE breast cancer PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES.
Dieu Vuong L; Ngoc Nguyen Q
Exp Oncol; 2023 Oct; 45(2):195-202. PubMed ID: 37824772
[TBL] [Abstract] [Full Text] [Related]
4. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
5. Hormone Receptor-Positive breast cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the mlh1 Variant 1835del3.
Kaplan HG; Whiteaker JR; Nelson B; Ivey RG; Lorentzen TD; Voytovich U; Zhao L; Corwin DJ; Resta R; Paulovich AG
J Natl Compr Canc Netw; 2023 Aug; 21(11):1110-1116. PubMed ID: 37643636
[TBL] [Abstract] [Full Text] [Related]
6. Causes and consequences of delayed diagnosis in breast cancer screening with a focus on mammographic features and tumour characteristics.
van der Veer EL; Lameijer J; Coolen AMP; Bluekens AMJ; Nederend J; Gielens M; Voogd A; Duijm L
Eur J Radiol; 2023 Oct; 167():111048. PubMed ID: 37634439
[TBL] [Abstract] [Full Text] [Related]
7. Discordant breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy.
Flores R; Roldan E; Pardo JA; Beight L; Ubellacker J; Fan B; Davis RB; James TA
Ann Surg Oncol; 2023 Dec; 30(13):8302-8307. PubMed ID: 37606840
[TBL] [Abstract] [Full Text] [Related]
8. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary breast and Ovarian cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract] [Full Text] [Related]
9. Germline pathogenic variants in metaplastic breast cancer patients and the emerging role of the BRCA1 gene.
Corso G; Marabelli M; Calvello M; Gandini S; Risti M; Feroce I; Mannucci S; Girardi A; De Scalzi AM; Magnoni F; Marino E; Bernard L; Veronesi P; Guerini-Rocco E; Barberis M; Guerrieri-Gonzaga A; Bonanni B
Eur J Hum Genet; 2023 Nov; 31(11):1275-1282. PubMed ID: 37460658
[TBL] [Abstract] [Full Text] [Related]
10. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
11. Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.
Feng Z; Zuo K; Ju X; Chen X; Yang W; Wen H; Yu L; Wu X
J Ovarian Res; 2023 Jun; 16(1):125. PubMed ID: 37386498
[TBL] [Abstract] [Full Text] [Related]
12. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
Zakaria NH; Hashad D; Saied MH; Hegazy N; Elkayal A; Tayae E
Hum Genomics; 2023 May; 17(1):43. PubMed ID: 37202799
[TBL] [Abstract] [Full Text] [Related]
13. Risk of Syndrome-Associated cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract] [Full Text] [Related]
14. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
15. Pilot study of gene mutations associated with Lynch syndrome in Slovak patients with breast cancer.
Krasničanová L; Saade R; Priščáková P; Gbelcová H; Kaľavská K; Karaba M; Benca J; Mego M; Repiská V
Klin Onkol; 2023; 36(2):130-134. PubMed ID: 37072247
[TBL] [Abstract] [Full Text] [Related]
16. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I
Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072
[TBL] [Abstract] [Full Text] [Related]
17. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
18. Identification of Germline Variants in Patients with Hereditary cancer Syndromes in Northeast Mexico.
Pérez-Ibave DC; Garza-Rodríguez ML; Noriega-Iriondo MF; Flores-Moreno SM; González-Geroniz MI; Espinoza-Velazco A; Castruita-Ávila AL; Alcorta-Núñez F; Zayas-Villanueva OA; González-Guerrero JF; Alcorta-Garza A; Vidal-Gutiérrez O; Burciaga-Flores CH
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833268
[TBL] [Abstract] [Full Text] [Related]
19. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
Kawamura M; Shirota H; Niihori T; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Kikuchi A; Tada H; Shimada M; Kawamorita N; Kanamori M; Sugiyama I; Tsubata M; Ichikawa H; Yasuda J; Furukawa T; Aoki Y; Ishioka C
J Hum Genet; 2023 Jun; 68(6):399-408. PubMed ID: 36804482
[TBL] [Abstract] [Full Text] [Related]
20. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
Adam F; Fluri M; Scherz A; Rabaglio M
BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
[TBL] [Abstract] [Full Text] [Related]
[Next]
